The neurodevelopmental and dopamine hypotheses are leading theories of the
pathoetiology of schizophrenia, but they were developed in isolation. However, since they …

The synaptic hypothesis of schizophrenia has been highly influential. However, new
approaches mean there has been a step-change in the evidence available, and some tenets …

Schizophrenia remains a major health burden, highlighting the need for new treatment
approaches. We consider the potential for targeting the trace amine (TA) system. We first …

Trace amine-associated receptor 1 (TAAR1) has emerged as a promising therapeutic target
for neuropsychiatric disorders due to its ability to modulate monoaminergic and …

Schizophrenia is associated with substantial unmet needs, highlighting the necessity for
new treatments. This narrative review compares the pharmacology, clinical trial data and …

Schizophrenia is a leading cause of global disability. Current pharmacotherapy for the
disease predominantly uses one mechanism—dopamine D2 receptor blockade—but often …

Despite 50+ years of drug discovery, current antipsychotics have limited efficacy against
negative and cognitive symptoms of schizophrenia, and are ineffective—with the exception …

Ulotaront (SEP-363856) is a trace-amine associated receptor 1 (TAAR1) agonist with 5-
HT1A receptor agonist activity in Phase 3 clinical development, with FDA Breakthrough …

Ulotaront is a trace amine-associated receptor 1 (TAAR1) agonist in Phase 3 clinical
development for the treatment of schizophrenia. Ulotaront was discovered through a unique …

The predominant inhibitory neurotransmitter in the brain, γ-aminobutyric acid (GABA), acts at
ionotropic GABAA receptors to counterbalance excitation and regulate neuronal firing …